Burnett John R, Hooper Amanda J, Hegele Robert A
Department of Clinical Biochemistry, Royal Perth Hospital & Fiona Stanley Hospital Network, PathWest Laboratory Medicine WA;, Faculty of Health & Medical Sciences, School of Medicine, University of Western Australia, Perth, Australia
Department of Clinical Biochemistry, Royal Perth Hospital & Fiona Stanley Hospital Network, PathWest Laboratory Medicine WA;, School of Medicine, University of Western Australia, Perth, Australia
Familial combined hypolipidemia is not associated with any pathologic signs or symptoms; diagnosis is suggested by low plasma concentrations of lipids. The lipid profile is one of hypocholesterolemia with low plasma low-density lipoprotein (LDL) cholesterol, low plasma high-density lipoprotein (HDL) cholesterol, low plasma triglycerides, and low plasma apolipoprotein (apo) B and apo A-I levels.
DIAGNOSIS/TESTING: The molecular diagnosis of familial combined hypolipidemia is established in a proband with suggestive laboratory findings and biallelic pathogenic variants in identified by molecular genetic testing.
No specific evaluation, management, or surveillance is required for individuals who have familial combined hypolipidemia; however, consultation with a medical geneticist, certified genetic counselor, or certified advanced genetic nurse to inform affected individuals and their families about the nature, mode of inheritance, and lack of specific clinical implications of familial combined hypolipidemia should be considered.
Familial combined hypolipidemia is inherited in an autosomal recessive manner. At conception, each sib of a person with FCH has a 25% chance of also having FCH, a 50% chance of being a heterozygous carrier, and a 25% chance of being unaffected and not a carrier. Heterozygotes for loss-of-function pathogenic variants have mildly reduced LDL cholesterol and triglyceride levels, and protection against atherosclerotic cardiovascular disease. Carrier testing for at-risk relatives is possible if the pathogenic pathogenic variants in the family are known. Prenatal and preimplantation genetic testing are also possible, but given the lack of clinical symptoms in most individuals who have FCH, this is not commonly pursued.
家族性混合型血脂异常不伴有任何病理体征或症状;血浆脂质浓度降低提示诊断。血脂谱表现为低胆固醇血症,伴有血浆低密度脂蛋白(LDL)胆固醇水平降低、血浆高密度脂蛋白(HDL)胆固醇水平降低、血浆甘油三酯水平降低以及血浆载脂蛋白(apo)B和apo A-I水平降低。
诊断/检测:家族性混合型血脂异常的分子诊断通过对先证者进行分子遗传学检测来确立,先证者具有提示性的实验室检查结果且鉴定出双等位基因致病性变异。
患有家族性混合型血脂异常的个体无需进行特定的评估、管理或监测;然而,应考虑咨询医学遗传学家、认证遗传咨询师或认证高级遗传护士,以便向受影响的个体及其家属告知家族性混合型血脂异常的性质、遗传方式以及缺乏特定临床意义等情况。
家族性混合型血脂异常以常染色体隐性方式遗传。在受孕时,家族性混合型血脂异常患者的每个同胞有25%的几率也患有该病,50%的几率为杂合子携带者,25%的几率不受影响且不是携带者。功能丧失性致病性变异的杂合子LDL胆固醇和甘油三酯水平轻度降低,并对动脉粥样硬化性心血管疾病有保护作用。如果家族中的致病性变异已知,则可为有风险的亲属进行携带者检测。产前和植入前基因检测也是可行的,但鉴于大多数家族性混合型血脂异常患者缺乏临床症状,这种检测并不常用。